Danielle Cabral
Neurology · Phoenix, AZNPI 1336432541
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Lilly USA, LLC at 37.7% of the total. 2025 is the largest year on record at $97,188, more than ten times the $104 reported in 2021. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $1105.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$58K
- Eli Lilly$51K
- Eisai Inc.$43K
- Genentech, Inc.$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$380
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$272
- plus $776 from 8 others
Across 152 payments — averaging $17,356 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$673K
- Biogen$595K
- Genentech, Inc.$547K
- AbbVie$408K
- Eisai Inc.$142K
- Novo Nordisk AS$119K
- plus $154K from 2 others
What the payments were for
- Consulting fees$50,61133%
- Speaking & faculty fees$86,54356%
- Travel & lodging$15,14410%
- Food & beverage$2,5012%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $58,374 |
| Eli Lilly | 22 | $50,830 |
| Eisai Inc. | 65 | $42,843 |
| Genentech, Inc. | 2 | $1,354 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $380 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $272 |
| Novo Nordisk | 3 | $200 |
| Genentech USA, Inc. | 2 | $145 |
| Otsuka America Pharmaceutical, Inc. | 2 | $144 |
| AbbVie | 1 | $114 |
| Biogen | 2 | $74 |
| C2n Diagnostics, LLC | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 1 | $27 |
| Corium, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$154,828 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 21 | $776 |
| Donepezil Hcl | 49 | $712 |
| Escitalopram Oxalate | 14 | $185 |
Paid to pharmacies, not to this prescriber.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.